login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

St Jude Medical establishes Cardiovascular Division


Thursday, 16 Nov 2006 00:00

St Jude Medical is combining its Cardiac Surgery and Cardiology divisions to create a new Cardiovascular Division, effective 1st January 2007. The Cardiovascular Division will focus on developing and bringing to market medical device technology and services to help patients who suffer from vascular disease or structural heart defects. The Cardiovascular Division will incorporate the activities currently managed by the Cardiac Surgery Division and by the Cardiology Division. The company will continue to have specialised cardiac surgery and cardiology sales forces.

According to Daniel J Starks, chairman, president and CEO of St Jude Medical, the company's cardiology and cardiac surgery businesses will be stronger together than each business is separately. Moreover, he claimed that by streamlining the organisation, the company can boost operating efficiencies and ultimately use the associated savings to invest in research and development.

The new Cardiovascular Division will be led by George J Fazio, who has served as president of St Jude Medical's Cardiac Surgery Division since 2004. Prior to his current role, Fazio was appointed president of St Jude Medical Europe in 2001. His preceding roles included president, Health Care Services for St Jude Medical, and general manager for St Jude Medical's operations in Canada.

Paul R Buckman, currently president of St Jude Medical's Cardiology Division, will become corporate vice president of Business Development. Since joining St Jude Medical in 2004 in his current role, Buckman has overseen a significant expansion of the Cardiology Division's products and programmes. The company is also initiating several changes to enhance the efficiency and effectiveness of its sales and customer service operations in certain international geographies.

As a result of these restructuring plans, St Jude Medical expects to incur a pre-tax charge of US$25 million to US$35 million during the third quarter of 2006. "The creation of a new Cardiovascular Division, together with the expansion of our sales force and recent new product introductions, are part of our comprehensive program to position St Jude Medical to deliver a minimum 15% growth in 2007 and beyond," Starks concluded.



Most popular


Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
Wednesday, 27 Aug 2014
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary ... Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published

No severe paravalvular leak with Acurate Neo TF
Monday, 29 Sep 2014
Data presented at PCR London Valves (28–30 September, London, UK) indicate that the Acurate Neo transfemoral TAVI system, which recently received the CE mark, is not associated with any incidences of ... No severe paravalvular leak with Acurate Neo TF

ABSORB II study shows Absorb is comparable to Xience drug-eluting stent
Wednesday, 17 Sep 2014
At one year, overall clinical outcomes for Absorb (Abbott) were comparable to Xience (Abbott), and people treated with Absorb experienced a significantly lower rate of angina. ABSORB II study shows Absorb is comparable to Xience drug-eluting stent

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Drug-coated balloons for the management of coronary artery disease
Thursday, 04 Sep 2014
Robert Byrne writes that although drug-coated balloon therapy has been a significant innovation with relevance for everyday practice, convincing data in the coronary arena exists thus far only for ... Drug-coated balloons for the management of coronary artery disease

Profiles


Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions